US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.99

-2.2085-4.89%

Post-market: 42.990.00000.00%16:10 EDT

Volume:3K

Turnover:133.25K

Market Cap:32.24M

PE:- -

High:45.58

Open:45.58

Low:42.95

Close:45.20

52wk High:45.58

52wk Low:31.44

Shares:750.00K

Float Shares:750.00K

Volume Ratio:0.12

T/O Rate:0.40%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

MT Newswires Live

Natera (NTRA) Gets a Buy from Citi

Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400

THOMSON REUTERS

Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million

Natera, Inc. : Citigroup Raises Target Price to $365 from $315

THOMSON REUTERS

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000

Natera, Inc. : Stephens Raises Target Price to $350 from $305

THOMSON REUTERS

Natera Partners with Kupando Therapeutics to Use Latitude ctDNA Test in Phase 1 Skin Cancer Trial

Natera to Support New Clinical Trial Assessing Ctdna Dynamics with Latitude™ in Advanced Skin Cancers

THOMSON REUTERS

Natera, Inc. : Piper Sandler Raises Target Price to $363.50 from $249

THOMSON REUTERS

China's Green Fuel Sector Shifts from Pilot Projects to Mass Production

Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares

Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing

Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan

Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?

Simply Wall St.

RBC Capital Remains a Buy on GH Research (GHRS)

Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 2,000 Common Shares Worth $641,800

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/HELX/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.9867,"timestamp":1791316800000,"preClose":45.1952,"halted":0,"volume":3036,"hourTrading":{"tag":"盘后","latestPrice":42.9867,"preClose":42.9867,"latestTime":"16:10 EDT","volume":8,"amount":343.963504,"timestamp":1791317405226,"change":0,"changeRate":0,"amplitude":0.000542},"delay":0,"changeRate":-0.04886580875845224,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"Post-Mkt","change":-2.2085,"latestTime":"10-06 17:12:29 EDT","open":45.58,"high":45.58,"low":42.95,"amount":133250,"amplitude":0.058192,"askPrice":64.95,"askSize":200,"bidPrice":22.47,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791331200000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":45.1952,"sharesOutstanding":650000,"nav":43.859,"aum":32894030.1,"dividendRate":0.003362,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.9867,"preClose":42.9867,"latestTime":"16:10 EDT","volume":8,"amount":343.963504,"timestamp":1791317405226,"change":0,"changeRate":0,"amplitude":0.000542},"volumeRatio":0.119903,"impliedVol":0.1194,"impliedVolPercentile":0.4183},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.119903,"shares":750000,"dividePrice":0.1445,"high":45.58,"amplitude":0.058192,"preClose":45.1952,"low":42.95,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":42.9867,"committee":-0.333333,"eps":0,"divideRate":0.003362,"volume":3036,"delay":0,"ttmEps":0,"open":45.58,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":44.4008,"twentyDayClose":41.6426,"sixtyDayClose":39.7282},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659124086","title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659124086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659124086?lang=en_us&edition=fundamental","pubTime":"2026-08-15 06:23","pubTimestamp":1786746202,"startTime":"0","endTime":"0","summary":"Krystal Biotech Director Dino A. Rossi disposes of USD 8.17 million in common sharesDirector Dino A. Rossi cut his Krystal Biotech stake to 50,000 shares on Aug. 14, 2026.Disposed of 25,000 common sha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL6DCXXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","PSCH","BK4139","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659140246","title":"Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659140246?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:11","pubTimestamp":1786720282,"startTime":"0","endTime":"0","summary":"Krystal Biotech  has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's neurotrophic keratitis program could be its next major catalyst, with pivotal data expected in early 2027, RBC said. Shares may rise 30% if results match the current standard of care, while a weak outcome might prompt a 15% decline, the report said.RBC forecasts peak NK sales of $2.1 billion in 2030, citing the established market and potential for the therapy to become a best-in-class treatment, though the outlook remains \"cautiously optimistic\" given limited clinical data.Vyjuvek holds more than 60% of the US market, while international launches are expected to drive the next phase of growth, the report said. RBC projects Vyjuvek peak sales of $1 billion by 2033 and pointed to H2 readouts in ocular DEB, cystic fibrosis a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","HELX","PSCH","BK4139","BK4581","KRYS","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659729143","title":"Natera (NTRA) Gets a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2659729143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659729143?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:57","pubTimestamp":1786705032,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick B Donnelly from Citi maintained a Buy rating on Natera, with a price target of $365.00. According to TipRanks, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/natera-ntra-gets-a-buy-from-citi-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/natera-ntra-gets-a-buy-from-citi-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","LU0106261612.USD","LU0345770308.USD","NTRA","LU0053671581.USD","LU0012050646.USD","LU1988902786.USD","HELX","LU0345770993.USD","LU0963586101.USD","LU1064131342.USD","BK4139","LU2324357040.USD","LU2065731478.USD","LU2065171402.SGD","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659428117","title":"Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2659428117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659428117?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:39","pubTimestamp":1786700394,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","HELX","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659719596","title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659719596","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659719596?lang=en_us&edition=fundamental","pubTime":"2026-08-14 07:21","pubTimestamp":1786663307,"startTime":"0","endTime":"0","summary":"Guardant Health Chief People Officer Terilyn Monroe disposes of common shares worth $7.61 millionGuardant Health Chief People Officer Terilyn J. Monroe cut her direct common stock stake to 22,979 shar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1rsYJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNOM","GH","LU0889565916.HKD","BK4551","FFOX","HELX","LU0320765992.SGD","BK4535","BK4196","LU0109394709.USD","PTH","LFSC","BK4588","GNMX","BK4585","GDOC","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659153712","title":"Natera, Inc. : Citigroup Raises Target Price to $365 from $315","url":"https://stock-news.laohu8.com/highlight/detail?id=2659153712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659153712?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:33","pubTimestamp":1786617184,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0012050646.USD","LU2324357040.USD","LU0106261612.USD","LU2065731478.USD","LU2264538146.SGD","LU2065171311.SGD","HELX","BK4139","LU0963586101.USD","GNOM","LU0053671581.USD","LU0345770993.USD","LU0345770308.USD","LU1064131342.USD","LU2065170008.USD","LU2065169927.USD","LU1988902786.USD","LU2065171402.SGD","NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659189872","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189872","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189872?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:34","pubTimestamp":1786577651,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sells 3,000 shares for $75,000Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 3,000 common shares on Aug. 10","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL6LzfyQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 3,000 Shares for $75,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658118976","title":"Natera, Inc. : Stephens Raises Target Price to $350 from $305","url":"https://stock-news.laohu8.com/highlight/detail?id=2658118976","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658118976?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:21","pubTimestamp":1786530064,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0345770308.USD","LU0106261612.USD","LU1988902786.USD","LU0053671581.USD","LU2065169927.USD","NTRA","LU2065170008.USD","BK4139","LU2065171402.SGD","GNOM","LU2264538146.SGD","LU0345770993.USD","LU0012050646.USD","LU2324357040.USD","LU0963586101.USD","LU2065171311.SGD","LU1064131342.USD","HELX","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975282","title":"Natera Partners with Kupando Therapeutics to Use Latitude ctDNA Test in Phase 1 Skin Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975282","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975282?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:01","pubTimestamp":1786528893,"startTime":"0","endTime":"0","summary":"Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trialNatera entered a collaboration with Kupando Therapeutics to support a Phase 1 trial of immunotherapy ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbT5KLV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065171402.SGD","LU2065171311.SGD","LU0053671581.USD","LU0106261612.USD","LU2065170008.USD","GNOM","LU0963586101.USD","LU2264538146.SGD","HELX","LU1064131342.USD","LU2065731478.USD","LU1988902786.USD","LU2065169927.USD","LU0345770993.USD","LU0012050646.USD","BK4139","NTRA","LU0345770308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975416","title":"Natera to Support New Clinical Trial Assessing Ctdna Dynamics with Latitude™ in Advanced Skin Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975416","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975416?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:00","pubTimestamp":1786528800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA74PDL6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0345770993.USD","LU2065731478.USD","LU2264538146.SGD","LU0345770308.USD","LU2065169927.USD","LU2324357040.USD","LU0106261612.USD","LU0963586101.USD","LU0012050646.USD","GNOM","LU2065171402.SGD","LU1988902786.USD","BK4139","LU2065171311.SGD","NTRA","LU1064131342.USD","HELX","LU2065170008.USD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975588","title":"Natera, Inc. : Piper Sandler Raises Target Price to $363.50 from $249","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975588?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:49","pubTimestamp":1786528145,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065170008.USD","LU0345770308.USD","LU0345770993.USD","LU2324357040.USD","LU2065169927.USD","LU2065731478.USD","LU0106261612.USD","LU2065171311.SGD","NTRA","HELX","LU2264538146.SGD","LU1988902786.USD","LU2065171402.SGD","LU0963586101.USD","LU1064131342.USD","BK4139","LU0012050646.USD","GNOM","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109741990","title":"China's Green Fuel Sector Shifts from Pilot Projects to Mass Production","url":"https://stock-news.laohu8.com/highlight/detail?id=1109741990","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109741990?lang=en_us&edition=fundamental","pubTime":"2026-08-12 11:20","pubTimestamp":1786504847,"startTime":"0","endTime":"0","summary":" As global climate governance enters a critical phase, green fuel, a key link between renewable energy and end-use consumption, is transitioning from an \"option\" to a \"necessity.\" Li Zhongwu,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658949165","title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2658949165","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658949165?lang=en_us&edition=fundamental","pubTime":"2026-08-12 06:23","pubTimestamp":1786487005,"startTime":"0","endTime":"0","summary":"Guardant Health Chief Commercial Officer Chris Freeman disposes of $ 10.75 million in common sharesGuardant Health Chief Commercial Officer Chris Freeman exercised stock options for 63,605 shares on A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4khYKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","FFOX","LU0320765992.SGD","EKG","HELX","BK4585","LFSC","GNMX","BK4551","GH","LU0109394709.USD","BK4535","LU0889565916.HKD","PTH","GDOC","BK4196","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658737957","title":"Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658737957","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658737957?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:36","pubTimestamp":1786401393,"startTime":"0","endTime":"0","summary":"An announcement from Qiagen ( ($QGEN) ) is now available. Qiagen N.V., a Netherlands-based life sciences and molecular diagnostics company headquar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/goldman-sachs-discloses-2-63-voting-interest-in-qiagen-via-afm-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/goldman-sachs-discloses-2-63-voting-interest-in-qiagen-via-afm-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFXG1179.USD","GS","LU1791807156.HKD","LU1894683264.USD","LU2237443895.HKD","LU0251142724.SGD","LU0061475181.USD","BMED","BK4588","LU2471134879.HKD","BK4127","LU1668664300.SGD","BK4504","LU0868494617.USD","LU1868836757.USD","LU1894683348.USD","IE00B19Z3B42.SGD","LU2237443549.SGD","LU2237443978.SGD","LU2750360641.GBP","IE0004086264.USD","LU2237443382.USD","BK4552","LU2237443465.HKD","IE0004091025.USD","BK4516","HELX","IE00B19Z3581.USD","LU0345770308.USD","LU2237443622.USD","LU1868837136.USD","BK4533","LU0251131958.USD","IE0034235188.USD","GNMX","LU0048573561.USD","LU2471134952.CNY","IE00BSNM7G36.USD","LU1868837300.USD","LU2471134796.USD","LU2237438978.USD","BK4550","BK4585","GSX","LU1804176565.USD","LU0345770993.USD","LU1868836591.USD","HTEC","LU2265009873.SGD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658599689","title":"Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2658599689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658599689?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:13","pubTimestamp":1786392812,"startTime":"0","endTime":"0","summary":"Guardant Health grants 46,044 RSUs to 149 new employees under inducement planGuardant Health set inducement RSU grants covering 46,044 common shares for 149 new non-executive hires, with an Aug. 3, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL208d3j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4588","GDOC","BK4551","EKG","PTH","BK4535","GNOM","GNMX","LFSC","LU0109394709.USD","LU0889565916.HKD","GH","LU0320765992.SGD","BK4585","FFOX","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660616","title":"Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660616","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660616?lang=en_us&edition=fundamental","pubTime":"2026-08-10 07:38","pubTimestamp":1786318701,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported second-quarter 2026 results showing a net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15.\nFor the first half of 2026, the company’s net loss expanded to US$34.11 million versus US$20.10 million in the prior-year period, highlighting a meaningful increase in cash burn and pressure on its financial profile.\nWe’ll now examine how this widening net...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/is-gh-researchs-rising-loss-per-share-reframing-the-ghrs-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GNOM","GHRS","LU0109394709.USD","BK4535","BK4551","EKG","LU0889565916.HKD","GH","BK4539","FFOX","BK4588","PSIL","GNMX","BK4007","LU0320765992.SGD","HELX","PTH","LFSC","BK4196","BK4585","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657229326","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657229326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657229326?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:45","pubTimestamp":1786153544,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","PSIL","FFOX","LFSC","HELX","LU0708994859.HKD","LU0128525929.USD","GSIB","GHRS","BK4588","EKG","LU0320765992.SGD","BK4585","LU0889565916.HKD","PTH","GNOM","BK4207","BK4551","LU0310800379.SGD","LU1267930573.SGD","BK4196","GNMX","BK4007","LU0029864427.USD","GDOC","BK4539","GH","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657622568","title":"Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 2,000 Common Shares Worth $641,800","url":"https://stock-news.laohu8.com/highlight/detail?id=2657622568","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657622568?lang=en_us&edition=fundamental","pubTime":"2026-08-08 09:35","pubTimestamp":1786152953,"startTime":"0","endTime":"0","summary":"Natera Executive Chairman Matthew Rabinowitz reports disposal of 2,000 common shares worth $641,800Natera Executive Chairman Matthew Rabinowitz reported a sale of 2,000 common shares on Aug. 7 at USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260808:nNDLSJWxn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera Executive Chairman Matthew Rabinowitz Reports Disposal of 2,000 Common Shares Worth $641,800","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU0345770308.USD","LU0345770993.USD","LU2324357040.USD","LU2065169927.USD","LU2065731478.USD","LU0106261612.USD","LU2065171311.SGD","NTRA","HELX","LU2264538146.SGD","LU1988902786.USD","LU2065171402.SGD","LU0963586101.USD","LU1064131342.USD","BK4139","LU0012050646.USD","GNOM","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629107","title":"Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629107","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629107?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:12","pubTimestamp":1786137124,"startTime":"0","endTime":"0","summary":"Canada's DRI Healthcare Q2 income rises, helped by milestone events in royalty portfolioOverviewCanada pharmaceutical royalty investor's Q2 total income rose to a record $50.1 mlnAdjusted EBITDA margi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N444109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","PBE","XNCR","IHE","IE0009354923.USD","HELX","LU1559883803.SGD","LGND","RPRX","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657260426","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657260426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657260426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:30","pubTimestamp":1786134613,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMD), GH Research (GHRS) and Scholar Rock...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-inmode-inmd-gh-research-ghrs-and-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EKG","LU0320765992.SGD","IBRN","BK4551","BK4007","LU0029874061.USD","GH","BK4539","LU0889565916.HKD","BK4585","XBI","GHRS","BK4581","PSIL","INMD","SRRK","GNMX","HELX","BK4137","THNR","XLV","BK4082","LABU","FFOX","LU0128526141.USD","BK4588","PTH","GNOM","BK4196","GDOC","HCSG","LFSC","LU0109394709.USD","BK4535","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}